| Stefanie Miles, LPC ASSOCIATE | |
|
12740 Hillcrest Rd Ste 270, Dallas, TX 75230-2086 | |
| (214) 487-6050 | |
| Not Available |
| Full Name | Stefanie Miles |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 12740 Hillcrest Rd Ste 270, Dallas, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053098095 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 205057 (Texas) | Secondary |
| 101YP2500X | Counselor - Professional | 91250 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stefanie Miles, LPC ASSOCIATE 4130 Prescott Ave, Dallas, TX 75219-2246 Ph: (817) 734-9432 | Stefanie Miles, LPC ASSOCIATE 12740 Hillcrest Rd Ste 270, Dallas, TX 75230-2086 Ph: (214) 487-6050 |
News Archive
Patients with epilepsy who underwent brain surgery soon after failing to respond to drug treatment, but who also continued to receive drug therapy, had a lower risk of seizures during the 2nd year of follow-up compared to patients who received drug treatment alone, according to a study in the March 7 issue of JAMA.
Results from a Phase 1b/2 trial suggest that an investigational microbiome-based, oral therapeutic drug is effective for the treatment of recurrent C. difficile infection. In a paper published online in the Journal of Infectious Diseases, a multi-institutional research team reports that treatment with the preparation, containing the spores of approximately 50 species of beneficial bacteria, successfully prevented recurrence of C. difficile infection (CDI) in patients with a history of multiple recurrent disease.
An international team of researchers led by geneticist Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL), has identified a mutation on human chromosome 16 that substantially increases risk for schizophrenia.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) action date of March 12 for its review of the exenatide once weekly new drug application (NDA).
According to Australian scientists, their latest stem cell research breakthrough will bring new treatments for a growing epidemic of chronic kidney disease. They are the first in the world to generate a type of stem cell from human kidney cells. The Melbourne scientists are hoping their discovery will have far-reaching effects in treating the disease.
› Verified 3 days ago
Keisha L. Butler, M.A., LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 N Central Expy, Suite 400-8, Dallas, TX 75201 Phone: 214-298-7647 Fax: 469-227-4251 | |
Mrs. Ashley Nicole Dye, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 4600 Samuell Blvd, Dallas, TX 75228 Phone: 214-381-7181 | |
Ms. Ana Cecilia Gutierrez, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 6220 Gaston Ave, Suite 501, Dallas, TX 75214 Phone: 972-904-7935 Fax: 972-838-1446 | |
Mr. James Richard White, LCDC Counselor Medicare: Not Enrolled in Medicare Practice Location: 8222 Douglas Ave, Suite 390, Dallas, TX 75225 Phone: 214-234-2400 Fax: 214-234-2401 | |
Dr. Cathey Soutter, PHD, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 17300 Preston Rd, Dallas, TX 75252 Phone: 972-733-6565 | |
Antonio Gonzales, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 8625 King George Dr, Suite 111, Dallas, TX 75235 Phone: 214-631-7002 Fax: 214-631-6698 | |
William Keith Palmer, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 5701 Maple Ave, Ste. 100, Dallas, TX 75235 Phone: 214-351-6600 Fax: 214-351-5046 |